Holen Sie sich die Stockscreener-App
2.07
7.59%
-0.17
Vorhandelsmarkt:
2.03
-0.04
-1.93%
Century Therapeutics Inc Aktie (IPSC) Neueste Nachrichten
Weekly Trades: Is Century Therapeutics Inc in a bullish channel2026 Stock Rankings & Fast Entry Momentum Alerts - baoquankhu1.vn
Downgrade Watch: Will Century Therapeutics Inc benefit from seasonality2026 Dividend Review & Breakout Confirmation Alerts - baoquankhu1.vn
Century Therapeutics reports 2025 results, advances cell therapy pipeline - MSN
Fed Meeting: Will Arch Capital Group Ltd outperform small cap indexes2026 Buyback Activity & Real-Time Volume Surge Alerts - baoquankhu1.vn
Dip Buying: How sensitive is Century Therapeutics Inc to inflationQuarterly Market Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Century Therapeutics Reports 2025 Results, Advances Cell Therapy Pipeline - MyChesCo
Century Therapeutics Hits New 52-Week High at $2.95 - Markets Mojo
Century Therapeutics Hits New 52-Week High of $3.04 Amid Market Fluctuations - Markets Mojo
Century Therapeutics (NASDAQ:IPSC) Insider Sells $25,693.80 in Stock - MarketBeat
Century Therapeutics (NASDAQ:IPSC) SVP Sells $17,959.65 in Stock - MarketBeat
Century Therapeutics (IPSC) SVP sells 7,043 shares to cover tax withholding - Stock Titan
Century Therapeutics (IPSC) officer sells shares to cover tax - Stock Titan
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Growth in Short Interest - MarketBeat
Zacks Research Downgrades Century Therapeutics (NASDAQ:IPSC) to Hold - MarketBeat
Century Therapeutics (IPSC) CEO has 55,397 shares withheld for RSU taxes - Stock Titan
Century Therapeutics (IPSC) CSO has 1,431 shares withheld for RSU tax obligations - Stock Titan
Century Therapeutics (IPSC) Receives a Buy from Clear Street - The Globe and Mail
Century Therapeutics (NASDAQ:IPSC) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Lantheus (LNTH), Century Therapeutics (IPSC) - The Globe and Mail
Century Therapeutics (IPSC) Swings To US$0.51 EPS Profit Challenging Persistent Loss Narratives - simplywall.st
IPSC (NASDAQ: IPSC) plans sale of 10,076 vested shares via Fidelity - Stock Titan
Century Therapeutics, Inc. announced that it has received $134.997458 million in funding from a group of investors - marketscreener.com
Century Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Century Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Century Therapeutics Reports 2025 Results and Pipeline Progress - TipRanks
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates - Investing News Network
CENTURY THERAPEUTICS ($IPSC) Releases Q4 2025 Earnings - Quiver Quantitative
Century Therapeutics 10-K Summary — Revenue: $— | EPS: $— - TradingView
Century Therapeutics 2025 net loss narrows beating estimates - TradingView
Century Therapeutics (NASDAQ: IPSC) slashes 2025 net loss on $109M revenue - Stock Titan
BRIEF-Century Therapeutics FY Net Income USD -9.58 Million - TradingView
Bearish Setup: Is Century Therapeutics Inc undervalued by DCF analysis2026 Catalysts & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Century Therapeutics (IPSC) officer auto-sells shares to cover RSU tax - Stock Titan
Century Therapeutics (IPSC) SVP Carr auto-sells shares to cover RSU tax - Stock Titan
Century Therapeutics (IPSC) to Release Quarterly Earnings on Wednesday - MarketBeat
Century Therapeutics (IPSC) CEO reports 463-share tax withholding on RSU vesting - Stock Titan
[144] Century Therapeutics, Inc. SEC Filing - Stock Titan
Century Therapeutics (NASDAQ:IPSC) Raised to "Hold" at Wall Street Zen - MarketBeat
Piper Sandler highlights Century Therapeutics (IPSC) cash runway through 2029, upcoming IND submission - MSN
Century Therapeutics to Showcase Promising Cell Therapy Data at ASGCT Annual Meeting - MSN
IPSC Financials: Income Statement, Balance Sheet & Cash Flow | Century Therapeutics, Inc. - Stock Titan
Should I buy Century Therapeutics Inc stock nowJuly 2025 Final Week & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 39.8% in February - MarketBeat
IPSC SEC FilingsCentury Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Closing: How does Century Therapeutics Inc perform in inflationary periodsDollar Strength & Entry Point Confirmation Signals - baoquankhu1.vn
Century Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Century Therapeutics (NASDAQ:IPSC) Coverage Initiated by Analysts at TD Cowen - Defense World
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Century Therapeutics (IPSC) - The Globe and Mail
Movement Recap: Is Century Therapeutics Inc forming a bullish divergenceQuarterly Portfolio Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Century Therapeutics to Participate in Upcoming Investor Conferences in March - Investing News Network
Century Therapeutics (NASDAQ:IPSC) Now Covered by Analysts at TD Cowen - MarketBeat
TD Cowen Initiates Century Therapeutics at Buy - marketscreener.com
TD Cowen initiates Century Therapeutics stock rating at Buy - Investing.com Australia
Financial Review: Century Therapeutics (NASDAQ:IPSC) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) - Defense World
IPSCCentury Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
What are the future prospects of Century Therapeutics Inc.2025 Support & Resistance & Fast Entry High Yield Stock Tips - mfd.ru
Century Therapeutics (IPSC) CEO has shares withheld for taxes - Stock Titan
Point72 discloses 6.8% Century Therapeutics (IPSC) stake in 13G/A - Stock Titan
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):